Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease
Details :
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Labs Opens a New Clinical Psychedelic Research Facility
Details :
Product Name : BMND02
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable